Literature DB >> 12499197

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.

Caroline Solas1, Alain Lafeuillade, Philippe Halfon, Stéphane Chadapaud, Gilles Hittinger, Bruno Lacarelle.   

Abstract

The variable penetration of antiretroviral drugs into sanctuary sites may contribute to the differential evolution of human immunodeficiency virus (HIV) and the emergence of drug resistance. We evaluated the penetration of indinavir, nelfinavir, and lopinavir-ritonavir (lopinavir/r) in the central nervous system, genital tract, and lymphoid tissue and assessed the correlation with residual viral replication. Plasma, cerebrospinal fluid (CSF), semen, and lymph node biopsy samples were collected from 41 HIV-infected patients on stable highly active antiretroviral therapy regimens to determine drug concentrations and HIV RNA levels. When HIV RNA was detectable, sequencing of the reverse transcriptase and protease genes was performed. Ratios of the concentration in semen/concentration in plasma were 1.9 for indinavir, 0.08 for nelfinavir, and 0.07 for lopinavir. Only indinavir was detectable in CSF, with a concentration in CSF/concentration in plasma ratio of 0.17. Differential penetration into lymphoid tissue was observed, with concentration in lymph node tissue/concentration in plasma ratios of 2.07, 0.58, and 0.21 for indinavir, nelfinavir, and lopinavir, respectively. HIV RNA levels were <50 copies/ml in all CSF samples of patients in whom HIV RNA was not detectable in plasma. HIV RNA was detectable in the semen of three patients (two patients receiving nelfinavir and one patient receiving lopinavir/r), and its detection was associated with multiple resistance mutations, while the viral load in plasma was undetectable. HIV RNA was detectable in all lymph node tissue samples. Differential drug penetration was observed among the three protease inhibitors in the sanctuary sites, but there was no correlation between drug levels and HIV RNA levels, suggesting that multiple factors are involved in the persistence of viral reservoirs. Further studies are required to clarify the role and clinical relevance of drug penetration in sanctuaries in terms of long-term efficacy and drug resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12499197      PMCID: PMC149042          DOI: 10.1128/AAC.47.1.238-243.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.

Authors:  A Mocroft; H Devereux; S Kinloch-de-Loes; D Wilson; S Madge; M Youle; M Tyrer; C Loveday; A N Phillips; M A Johnson
Journal:  AIDS       Date:  2000-07-28       Impact factor: 4.177

2.  Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.

Authors:  J Durant; P Clevenbergh; R Garraffo; P Halfon; S Icard; P Del Giudice; N Montagne; J M Schapiro; P Dellamonica
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

3.  Persistence of human immunodeficiency virus in semen after adding indinavir to combination antiretroviral therapy.

Authors:  K H Mayer; S Boswell; R Goldstein; W Lo; C Xu; L Tucker; M P DePasquale; R D'Aquila; D J Anderson
Journal:  Clin Infect Dis       Date:  1999-06       Impact factor: 9.079

4.  Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.

Authors:  X J Zhou; D V Havlir; D D Richman; E P Acosta; M Hirsch; A C Collier; P Tebas; J P Sommadossi
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

5.  Comparison of human immunodeficiency virus type 1 RNA sequence heterogeneity in cerebrospinal fluid and plasma.

Authors:  Y W Tang; J T Huong; R M Lloyd; P Spearman; D W Haas
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

6.  Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.

Authors:  H F Günthard; D V Havlir; S Fiscus; Z Q Zhang; J Eron; J Mellors; R Gulick; S D Frost; A J Brown; W Schleif; F Valentine; L Jonas; A Meibohm; C C Ignacio; R Isaacs; R Gamagami; E Emini; A Haase; D D Richman; J K Wong
Journal:  J Infect Dis       Date:  2001-04-10       Impact factor: 5.226

7.  Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.

Authors:  A S Pereira; A D Kashuba; S A Fiscus; J E Hall; R R Tidwell; L Troiani; J A Dunn; J J Eron; M S Cohen
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

8.  Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group.

Authors:  S L Letendre; E V Capparelli; R J Ellis; J A McCutchan
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

9.  Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy.

Authors:  A Si-Mohamed; M D Kazatchkine; I Heard; C Goujon; T Prazuck; G Aymard; G Cessot; Y H Kuo; M C Bernard; B Diquet; J E Malkin; L Gutmann; L Bélec
Journal:  J Infect Dis       Date:  2000-07-06       Impact factor: 5.226

10.  Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection.

Authors:  D W Haas; J Stone; L A Clough; B Johnson; P Spearman; V L Harris; J Nicotera; R H Johnson; S Raffanti; L Zhong; P Bergqwist; S Chamberlin; V Hoagland; W D Ju
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

View more
  65 in total

1.  Evolution and recombination of genes encoding HIV-1 drug resistance and tropism during antiretroviral therapy.

Authors:  Binshan Shi; Christina Kitchen; Barbara Weiser; Douglas Mayers; Brian Foley; Kimdar Kemal; Kathryn Anastos; Marc Suchard; Monica Parker; Cheryl Brunner; Harold Burger
Journal:  Virology       Date:  2010-05-08       Impact factor: 3.616

2.  Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques.

Authors:  Magdalena Magierowska; Flavien Bernardin; Seema Garg; Silvija Staprans; Michael D Miller; Koen K A Van Rompay; Eric L Delwart
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

3.  Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.

Authors:  Christopher J Destache; Todd Belgum; Michael Goede; Annemarie Shibata; Michael A Belshan
Journal:  J Antimicrob Chemother       Date:  2010-08-21       Impact factor: 5.790

4.  Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.

Authors:  G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

5.  Susceptibility of human testis to human immunodeficiency virus-1 infection in situ and in vitro.

Authors:  Vanessa Roulet; Anne-Pascale Satie; Annick Ruffault; Anna Le Tortorec; Hélène Denis; Odile Guist'hau; Jean-Jacques Patard; Nathalie Rioux-Leclerq; Janine Gicquel; Bernard Jégou; Nathalie Dejucq-Rainsford
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

6.  Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir.

Authors:  Sonya J Snedecor; Sean M Sullivan; Rodney J Y Ho
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

7.  Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.

Authors:  Erin Burgunder; John K Fallon; Nicole White; Amanda P Schauer; Craig Sykes; Leila Remling-Mulder; Martina Kovarova; Lourdes Adamson; Paul Luciw; J Victor Garcia; Ramesh Akkina; Philip C Smith; Angela D M Kashuba
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

8.  Lymph node effective vascular permeability and chemotherapy uptake.

Authors:  Eelco F J Meijer; Cedric Blatter; Ivy X Chen; Echoe Bouta; Dennis Jones; Ethel R Pereira; Keehoon Jung; Benjamin J Vakoc; James W Baish; Timothy P Padera
Journal:  Microcirculation       Date:  2017-08       Impact factor: 2.628

9.  Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.

Authors:  Theresa K Smit; Bruce J Brew; Wallace Tourtellotte; Susan Morgello; Benjamin B Gelman; Nitin K Saksena
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 10.  Overcoming pharmacologic sanctuaries.

Authors:  Theodore J Cory; Timothy W Schacker; Mario Stevenson; Courtney V Fletcher
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.